Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director | June 11, 2026 | June 12, 2026 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,140 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 35,000 · Balance 168,140 F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.
F2: Includes shares of restricted common stock.
TG THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Tracking UnitSEC Table II · derivative / convertible security | Direct | 8,325 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 8,325 · Balance 8,325 F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant.
F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-10 · Grant · Acquired 600,000 · Balance 1,374,352 F1: Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"). Row 2 · 2020-06-10 · Other · Disposed 1,374,352 · Balance 0 F2: Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2026-01-07 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3: All options were vested and exercisable as of the effective time of the merger. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Disposition to issuer · Disposed 44,058 · Balance 0 F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement").
F2: Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F3: All options were vested and exercisable as of the effective time of the merger.
F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 12, 2026 20:12 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-073461 · tm2617536-4_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,140 F1 · shares: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 21:02 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantStock Tracking Unit · Derivative | 8,325 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-26-020676 · rdgdoc.xml · derivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,325 Underlying: Common Stock · 8,325 shares Expires not disclosed F1 · derivative.exercise_price: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2 · derivative.exercise_date: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 20:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-058915 · tm2517867-1_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,140 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:46 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 14,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-25-020543 · rdgdoc.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 279,653 F1 · shares: Reflects a grant of restricted shares that will vest on June 12, 2026. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 19, 2024 Filed Jun 20, 2024 22:05 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 22,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-020849 · rdgdoc.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,935 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2025. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 20:22 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-071285 · tm2416958-2_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,140 F1 · shares: The 30,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the board on such dates. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 21:01 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-105394 · tm2327273-3_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 242,685 F1 · shares: Reflects a grant of restricted shares that will vest on June 14, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 12:15 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-072605 · tm2319007-1_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,140 F1 · shares: The 18,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the board on such dates. Read SEC document |
| July 20, 2022 Filed Jul 22, 2022 20:31 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCommon Stock | 43,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-082020 · tm2221660-3_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,685 F1 · shares: Reflects a grant of restricted shares that will vest on June 15, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| May 12, 2022 Filed May 16, 2022 12:33 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 6,000 | $17.40 | $104,400.00 |
DisclosureSEC source: 0001104659-22-060913 · tm2215423-3_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,140 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $17.16 to $17.66. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:47 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantStock Options (right to buy) · Derivative | 15,000 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001104659-22-042820 · tm2211420-5_4seq1.xml · derivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-04-01 F1 · derivative.exercise_date: The options will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:25 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-084258 · tm2120405-3_4seq1.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,953 F1 · shares: Reflects a grant of restricted shares that will vest on June 18, 2024. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 23:50 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-076545 · tm2022959-4_4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,953 F1 · shares: Reflects a grant of restricted shares that will vest on June 22, 2023. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:18 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 44,058 | Not disclosed Strike: $4.12 | Not disclosed |
DisclosureSEC source: 0001104659-20-071835 · a4.xml · derivative · entry 4 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,058 shares Expires 2026-02-24 F4 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:18 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $5.77 | Not disclosed |
DisclosureSEC source: 0001104659-20-071835 · a4.xml · derivative · entry 3 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-01-07 F4 · price: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3 · derivative.exercise_date: All options were vested and exercisable as of the effective time of the merger. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:18 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | OtherCommon Stock | 1,374,352 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-071835 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. Read SEC document |
| June 10, 2020 Filed Jun 10, 2020 11:18 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-071835 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,352 F1 · shares: Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"). Read SEC document |
| March 10, 2020 Filed Mar 13, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 16,704 | $4.91 | $82,016.64 |
DisclosureSEC source: 0001104659-20-033491 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 771,764 F4 · shares: In connection with the vesting of 32,867 shares on March 9, 2020, a total of 16,704 of such shares were sold by the Company on March 10, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F5 · price: Reflects the weighted average sale price. The range of prices for the shares sold on March 10, 2020 was $4.67 to $5.03. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F6 · balance_after: Of the listed shares, 373,285 shares are restricted stock. Read SEC document |
| March 09, 2020 Filed Mar 13, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 9,487 | $5.08 | $48,193.96 |
DisclosureSEC source: 0001104659-20-033491 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,468 F1 · shares: In connection with the vesting of 17,576 shares on March 8, 2020, a total of 9,487 of such shares were sold by the Company on March 9, 2020 in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on March 9, 2020 was $5.00 to $5.22. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F3 · balance_after: Of the listed shares, 406,152 shares are restricted stock. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 11,547 | $6.42 | $74,131.74 |
DisclosureSEC source: 0001104659-20-027397 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 797,955 F1 · shares: In connection with the vesting of 21,996 shares on February 24, 2020, a total of 11,547 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the Issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on February 25, 2020 was $6.26 to $6.67. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the listed shares, 423,728 shares are restricted stock. Read SEC document |
| February 10, 2020 Filed Feb 14, 2020 21:29 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 208,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-022140 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,502 F1 · shares: The 208,417 restricted shares will vest in three installments as follows: 69,473 shares on April 14, 2021; 69,472 shares on March 30, 2022; and 69,472 shares on January 18, 2023. F2 · balance_after: Of the listed shares, 445,724 shares are restricted stock. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 22,139 | $7.02 | $155,415.78 |
DisclosureSEC source: 0001104659-20-006882 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 601,085 F1 · shares: In connection with the vesting of 45,024 shares on January 21, 2020, a total of 22,139 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on January 22, 2020 was $6.98 to $7.05. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 237,307 shares are restricted stock. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 21:16 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 13,228 | $10.37 | $137,174.36 |
DisclosureSEC source: 0001104659-20-003149 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 623,224 F1 · shares: In connection with the vesting of 25,000 shares on January 7, 2020, a total of 13,228 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on January 8, 2020 was $10.29 to $10.52. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 282,331 shares are restricted stock. Read SEC document |
| December 27, 2019 Filed Jan 3, 2020 17:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 2,022 | $10.48 | $21,190.56 |
DisclosureSEC source: 0001104659-20-000980 · a4.xml · nonDerivative · entry 4 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 636,452 F1 · shares: In connection with the vesting of 94,304 shares on December 21, 2019, a total of 46,312 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 4,319 shares were sold on December 23, 2019; 24,477 shares were sold on December 24, 2019; 15,494 shares were sold on December 26, 2019; and 2,022 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 307,331 shares are restricted stock. Read SEC document |
| December 26, 2019 Filed Jan 3, 2020 17:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 15,494 | $10.75 | $166,560.50 |
DisclosureSEC source: 0001104659-20-000980 · a4.xml · nonDerivative · entry 3 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 638,474 F1 · shares: In connection with the vesting of 94,304 shares on December 21, 2019, a total of 46,312 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 4,319 shares were sold on December 23, 2019; 24,477 shares were sold on December 24, 2019; 15,494 shares were sold on December 26, 2019; and 2,022 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 307,331 shares are restricted stock. Read SEC document |
| December 24, 2019 Filed Jan 3, 2020 17:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 24,477 | $10.97 | $268,512.69 |
DisclosureSEC source: 0001104659-20-000980 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,968 F1 · shares: In connection with the vesting of 94,304 shares on December 21, 2019, a total of 46,312 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 4,319 shares were sold on December 23, 2019; 24,477 shares were sold on December 24, 2019; 15,494 shares were sold on December 26, 2019; and 2,022 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 307,331 shares are restricted stock. Read SEC document |
| December 23, 2019 Filed Jan 3, 2020 17:19 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 4,319 | $10.58 | $45,695.02 |
DisclosureSEC source: 0001104659-20-000980 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 678,445 F1 · shares: In connection with the vesting of 94,304 shares on December 21, 2019, a total of 46,312 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. 4,319 shares were sold on December 23, 2019; 24,477 shares were sold on December 24, 2019; 15,494 shares were sold on December 26, 2019; and 2,022 shares were sold on December 27, 2019. F2 · price: Reflects the weighted average sale price. The range of prices for the shares sold on December 23, 2019 was $10.37 to $10.75; the range of prices for the shares sold on December 24, 2019 was $10.81 to $11.15; the range of prices for the shares sold on December 26, 2019 was $10.52 to $11.20; and the range of prices for the shares sold on December 27, 2019 was $10.34 to $10.76. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price F3 · balance_after: Of the listed shares, 307,331 shares are restricted stock. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 21:11 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 27,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-19-010891 · section16.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 143,953 F1 · shares: Reflects a grant of restricted shares that will vest on June 13, 2022. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| June 26, 2019 Filed Jun 28, 2019 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 12,508 | $14.77 | $184,743.16 |
DisclosureSEC source: 0001104659-19-038310 · a4.xml · nonDerivative · entry 3 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 682,764 F7 · shares: In connection with the vesting of 87,500 shares on June 21, 2019, a total of 12,508 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F8 · price: Reflects the weighted average sale price. The range of prices for such transaction is $14.55 to $15.03. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F9 · balance_after: Of the 682,764 shares, 401,635 shares are restricted stock. Read SEC document |
| June 25, 2019 Filed Jun 28, 2019 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 25,500 | $15.07 | $384,285.00 |
DisclosureSEC source: 0001104659-19-038310 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 695,272 F4 · shares: In connection with the vesting of 87,500 shares on June 21, 2019, a total of 25,500 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F5 · price: Reflects the weighted average sale price. The range of prices for such transaction is $14.64 to $15.28. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F6 · balance_after: Of the 695,272 shares, 401,635 shares are restricted stock. Read SEC document |
| June 24, 2019 Filed Jun 28, 2019 17:17 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 9,107 | $15.49 | $141,067.43 |
DisclosureSEC source: 0001104659-19-038310 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 720,772 F1 · shares: In connection with the vesting of 87,500 shares on June 21, 2019, a total of 9,107 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $14.83 to $15.79. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 720,772 shares, 401,635 shares are restricted stock. Read SEC document |
| June 12, 2019 Filed Feb 14, 2020 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GiftStock Options (right to buy) · Derivative | 132,176 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0001104659-20-022141 · a5.xml · derivative · entry 5 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 132,176 shares Expires 2026-02-24 F1 · kind: On June 12, 2019, options to purchase shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Hoberman's minor children. Mr. Hoberman is not a trustee of the trust and has no investment control over the securities held by the trust. F2 · derivative.exercise_date: Represents options to purchase shares of common stock that vested 25% per year on each of the first four anniversaries of the grant date. All options have a 10-year life. Read SEC document |
| June 12, 2019 Filed Feb 14, 2020 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GiftStock Options (right to buy) · Derivative | 75,000 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0001104659-20-022141 · a5.xml · derivative · entry 4 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-01-07 F1 · kind: On June 12, 2019, options to purchase shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Hoberman's minor children. Mr. Hoberman is not a trustee of the trust and has no investment control over the securities held by the trust. F4 · derivative.exercise_date: Represents options to purchase shares of common stock that vested in three equal installments on each of the first three anniversaries of the January 7, 2016 grant date. Read SEC document |
| June 12, 2019 Filed Feb 14, 2020 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GiftStock Options (right to buy) · Derivative | 97,580 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001104659-20-022141 · a5.xml · derivative · entry 3 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 97,580 shares Expires 2022-03-09 F1 · kind: On June 12, 2019, options to purchase shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Hoberman's minor children. Mr. Hoberman is not a trustee of the trust and has no investment control over the securities held by the trust. F3 · derivative.exercise_date: Represents options to purchase shares of common stock that vested 25% on the first anniversary and the remaining 75% vested quarterly over a three-year period. Read SEC document |
| June 12, 2019 Filed Feb 14, 2020 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GiftStock Options (right to buy) · Derivative | 18,070 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-20-022141 · a5.xml · derivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,070 shares Expires 2021-03-08 F1 · kind: On June 12, 2019, options to purchase shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Hoberman's minor children. Mr. Hoberman is not a trustee of the trust and has no investment control over the securities held by the trust. Read SEC document |
| June 12, 2019 Filed Feb 14, 2020 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GiftStock Options (right to buy) · Derivative | 18,070 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001104659-20-022141 · a5.xml · derivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,070 shares Expires 2021-03-08 F1 · kind: On June 12, 2019, options to purchase shares of common stock were transferred into an irrevocable trust for the benefit of Mr. Hoberman's minor children. Mr. Hoberman is not a trustee of the trust and has no investment control over the securities held by the trust. F2 · derivative.exercise_date: Represents options to purchase shares of common stock that vested 25% per year on each of the first four anniversaries of the grant date. All options have a 10-year life. Read SEC document |
| May 14, 2019 Filed May 17, 2019 21:29 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 25,817 | $14.27 | $368,408.59 |
DisclosureSEC source: 0001104659-19-030357 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 729,879 F1 · shares: In connection with the vesting of 50,000 shares on May 13, 2019, a total of 25,817 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $14.15 to $14.53. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 729,879 shares, 489,135 shares are restricted stock. Read SEC document |
| March 12, 2019 Filed Mar 15, 2019 21:00 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 981 | $11.04 | $10,830.24 |
DisclosureSEC source: 0001104659-19-015344 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 755,696 F1 · shares: In connection with the vesting of 17,576 shares on March 8, 2019 and 32,867 shares on March 9, 2019, a total of 26,082 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F4 · price: Reflects the weighted average sale price. The range of prices for such transaction is $11.02 to $11.25. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F5 · balance_after: Of the 755,696 shares, 539,135 shares are restricted stock. Read SEC document |
| March 11, 2019 Filed Mar 15, 2019 21:00 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 25,101 | $11.11 | $278,872.11 |
DisclosureSEC source: 0001104659-19-015344 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 756,677 F1 · shares: In connection with the vesting of 17,576 shares on March 8, 2019 and 32,867 shares on March 9, 2019, a total of 26,082 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $11.00 to $11.52. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 756,677 shares, 539,135 shares are restricted stock. Read SEC document |
| March 07, 2019 Filed Mar 8, 2019 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 2,995 | $11.36 | $34,023.20 |
DisclosureSEC source: 0001104659-19-013684 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,778 F1 · shares: In connection with the vesting of 6,094 shares on March 6, 2019, a total of 2,995 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $11.23 to $11.54. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 781,778 shares, 589,578 shares are restricted stock. Read SEC document |
| February 25, 2019 Filed Feb 27, 2019 21:10 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 10,557 | $12.05 | $127,211.85 |
DisclosureSEC source: 0001104659-19-011257 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,773 F1 · shares: In connection with the vesting of 21,996 shares on February 24, 2019, a total of 10,557 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $12.04 to $12.05. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 784,773 shares, 595,672 shares are restricted stock. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 20:54 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 13,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-006898 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 795,330 F3 · shares: The 13,607 restricted shares will vest in two installments as follows: 6,804 shares on December 21, 2019 and 6,803 shares on December 21, 2020. F4 · balance_after: Of the 795,330 shares, 617,668 shares are restricted stock. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 20:54 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 135,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-006898 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 781,723 F1 · shares: The 135,071 restricted shares will vest in three installments as follows: 45,024 shares on January 21, 2020; 45,024 shares on April 13, 2021; and 45,023 shares on March 29, 2022. F2 · balance_after: Of the 781,723 shares, 604,061 shares are restricted stock. Read SEC document |
| January 08, 2019 Filed Jan 11, 2019 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 13,547 | $10.15 | $137,502.05 |
DisclosureSEC source: 0001104659-19-001650 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 646,652 F1 · shares: In connection with the vesting of 25,000 shares on January 8, 2019, a total of 13,547 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $9.94 to $10.26. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 646,652 shares, 468,990 shares are restricted stock. Read SEC document |
| November 26, 2018 Filed Nov 30, 2018 20:59 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 26,296 | $11.85 | $311,607.60 |
DisclosureSEC source: 0001104659-18-070899 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 659,738 F1 · shares: In connection with the vesting of 50,000 shares on November 13, 2018, a total of 26,296 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $11.65 to $12.10. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 659,738 shares, 493,990 shares are restricted stock. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 21:58 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-056986 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 686,034 F2 · shares: In the event the U.S. Food and Drug Administration approves of the Company's Biologics License Application with respect to ELZONRIS (the "Approval Milestone"), 87,500 shares will vest six months following the achievement of the Approval Milestone and 87,500 shares will vest on the first anniversary of the achievement of the Approval Milestone. Or, such shares will vest as follows: 58,334 restricted shares on September 12, 2021, and 58,333 restricted shares on each of September 12, 2022 and September 12, 2023. F3 · balance_after: Of the 684,594 shares, 543,990 shares are restricted stock. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 21:58 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-056986 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,034 F1 · shares: The 100,000 restricted shares will vest in two installments as follows: 50,000 shares will vest on November 13, 2018 and 50,000 shares will vest on May 13, 2019. Read SEC document |
| June 26, 2018 Filed Jun 28, 2018 21:00 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-18-007121 · section16.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,905 F1 · shares: Reflects a grant of restricted shares that will vest on June 26, 2021. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods. Read SEC document |
| March 13, 2018 Filed Mar 14, 2018 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 12,746 | $16.82 | $214,387.72 |
DisclosureSEC source: 0001104659-18-017586 · a4.xml · nonDerivative · entry 3 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,594 F7 · shares: In connection with the vesting of 25,000 shares on March 12, 2018, a total of 12,746 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F8 · price: Reflects the weighted average sale price. The range of prices for such transaction is $16.55 to $17.18. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F9 · balance_after: Of the 409,594 shares, 268,990 shares are restricted stock. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 3,299 | $18.24 | $60,173.76 |
DisclosureSEC source: 0001104659-18-017586 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 422,340 F4 · shares: In connection with the vesting of 32,868 shares on March 9, 2018, a total of 3,299 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F5 · price: Reflects the weighted average sale price. The range of prices for such transaction is $17.73 to $18.70. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F6 · balance_after: Of the 422,340 shares, 293,990 shares are restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.